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CYP2C19 genotyping is used to guide antiplatelet therapy after percutaneous coronary 
intervention (PCI). This study evaluated the potential impact of CYP2C19 and multigene 
pharmacogenomic (PGx) testing on medications beyond antiplatelet therapy in a real-world 
cohort of PCI patients that underwent CYP2C19 testing. Multiple medications with actionable 
PGx recommendations, notably proton pump inhibitors, antidepressants and opioids, were 
commonly prescribed. Approximately 50% received a CYP2C19 metabolized medication 
beyond clopidogrel, and 7% met criteria for a CYP2C19 genotype-guided intervention. A 
simulation analysis projected that 17.5 PGx-guided medication interventions per 100 PCI 
patients could have been made if multigene PGx results were available. This suggests that 
CYP2C19 and multigene PGx results could be used to optimize medication prescribing beyond 
antiplatelet therapy in PCI patients. 
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Selecting treatment strategies that account for individual genetic differences offers 
enormous potential to improve health outcomes and lower healthcare costs. While more than 
170 medications have germline genetic information in the drug label approved by the U.S. Food 
and Drug Administration (FDA), pharmacogenomic (PGx) testing is not routinely used to guide 
prescribing in clinical settings.[1,3] PGx-guided prescribing offers the potential to optimize drug 
selection and dosing based on patient-specific genetic factors. However, in order for a gene-
drug pair to be considered clinically actionable, there must be sufficient supporting evidence, an 
approved genetic test, and an alternative dose or drug for individuals with the ‘at risk’ genotype. 
Moreover, a structured approach to implement PGx-guided prescribing must be in place.[3]  
The Clinical Pharmacogenomics Implementation Consortium (CPIC) publishes 
guidelines that systematically evaluate genotype and drug phenotype association data, and 
translates this information into evidence-based recommendations for clinicians.[4] To date, 
CPIC has identified over 80 medications impacted by approximately 20 genes with Level A or B 
evidence, whereby a prescribing action is recommended to avoid an adverse medication 
outcome and alternative therapies or dosing are highly likely to be effective and safe.[3–5] While 
approximately 7% of FDA approved medications have actionable PGx recommendations based 
on CPIC Level A or B evidence, these medications have been estimated to represent 18% of 
the outpatient medications prescribed in the U.S.[3] Furthermore, many of the at-risk genotypes 
that affect these medications are common, as 99% of individuals carry at least one actionable 
PGx genotype.[6,7]  
Currently, when PGx testing is performed, genotyping typically occurs for putatively 
functional single nucleotide polymorphisms in a single gene and in a reactive manner after it has 
been determined that the patient will be prescribed a drug with actionable PGx 
recommendations. Notably, implementation of CYP2C19 genotype testing to guide the selection 
of antiplatelet therapy in patients with coronary artery disease (CAD) undergoing percutaneous 
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coronary intervention (PCI) has become increasingly common.[8,9] It is now well-established 
that patients with nonfunctional CYP2C19 variant alleles are at increased risk of adverse 
cardiovascular events after stent placement when treated with clopidogrel, which remains the 
most commonly used P2Y12 inhibitor after PCI.[10–12] Consequently, use of alternative therapy 
(prasugrel or ticagrelor) is recommended in CYP2C19 nonfunctional allele carriers, which 
comprise approximately 30% of the U.S. population.[13] 
Preemptive PGx testing, in which a patient is simultaneously tested for multiple PGx 
actionable genes in advance of medication prescribing, likely offers advantages over single-
gene testing due to decreasing genotype costs secondary to technological advancements and 
the potential benefits associated with PGx-guided prescribing.[14] However, the patient 
populations in which multigene preemptive PGx testing offers the greatest impact to avoid 
adverse drug outcomes have not been clearly defined, evaluated and validated. Due to the 
benefit of CYP2C19 genotype-guided antiplatelet therapy, and high prevalence of polypharmacy 
among CAD patients due to advanced age and common comorbidities such as hyperlipidemia, 
hypertension, atrial fibrillation and depression, the cardiac catheterization laboratory offers 
potential to identify a high-risk population in which institutions can implement multigene PGx 
testing.[15–18]  
We hypothesize that PCI patients undergoing CYP2C19 genetic testing to guide 
antiplatelet therapy selection are also prescribed multiple medications, in addition to clopidogrel, 
that have actionable PGx recommendations for at-risk genotypes in CYP2C19 and other 
established pharmacogenes. However, it is not known how frequently this patient population is 
prescribed medications with actionable PGx recommendations and carry an at-risk genotype 
that increases risk for therapeutic failure or adverse event that could be avoided by preemptive 
PGx-based prescribing. Therefore, the objective of this study was to 1) describe the frequency 
of genetically actionable medication use beyond antiplatelet therapy in a real-world cohort of 
PCI patients that underwent CYP2C19 genetic testing, 2) determine the proportion of PCI 
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patients at risk for an adverse medication outcome based on their known CYP2C19 metabolizer 
phenotype, and 3) evaluate the projected impact of multigene PGx testing on medication 
prescribing in CAD patients undergoing PCI. 
 
Methods 
Study Design and Population 
This single center, retrospective observational cohort study included 646 consecutive 
patients 18 years of age or older who underwent PCI with coronary artery stent placement at an 
academic medical center between January 1, 2015 to December 31, 2015. Patients were 
eligible for clinical CYP2C19 genetic testing at the interventional cardiologist’s discretion, which 
was clinically implemented in 2012 to guide antiplatelet therapy prescribing in high-risk 
patients.[9,19] Patients who died before discharge from their PCI hospitalization were excluded 
from this analysis. The study was approved by the Institutional Review Board. Due to the 
retrospective nature of the study, informed consent was not required. 
 
Data Abstraction 
Demographic, clinical, medication, and CYP2C19 genotype data were manually 
abstracted from encounters in the electronic health record (EHR). Physician-documented 
comorbid conditions were collected from the patient past medical history. CYP2C19 metabolizer 
phenotypes were assigned based on CPIC guidelines: ultrarapid (UM; *17/*17), rapid (RM; 
*1/*17), normal (NM; *1/*1), intermediate (IM; *1/*2, *1/*3, *2/*17, or *3/*17), or poor (PM; *2/*2, 
*2/*3, or *3/*3).[20] Medication use was reported for the total study population, as well as within 
the stratum of the cohort that underwent CYP2C19 genotype testing.  
Because antiplatelet therapy with aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or 
ticagrelor) is indicated in all PCI patients, and CYP2C19 genotype is already used clinically to 
guide antiplatelet therapy at our institution, the frequency of medication use beyond clopidogrel 
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was the focus of the current analysis. Prescribed medications with CPIC Level A or B evidence 
used to treat chronic medical conditions were collected at discharge from the index PCI 
hospitalization and at up to two follow-up encounters within one year of the index PCI 
(Supplemental Table 1).[4,5] Outpatient cardiology and primary care provider (PCP) follow-up 
visits with a full medication history over one year were prioritized for data abstraction. Since PCI 
patients are treated by cardiologists, 6 additional medications used to treat cardiovascular 
diseases (CVD) with genetic information in the FDA label and CPIC Level C-D evidence 
(propafenone, carvedilol, metoprolol, propranolol, rosuvastatin and hydralazine) were 
collected.[1,5] Medications used for the treatment of rare conditions and medications not 
commonly used in the U.S. were excluded due to the low likelihood of use one year after PCI. 
Medications used transiently, such as antibiotics, antifungals and anesthesiology drugs, were 
also excluded because documentation of use in hospital discharge and outpatient encounters 
would likely underrepresent their actual use. Based on these criteria, 5 CPIC Level A drugs and 
31 Level B drugs were excluded from data collection, and 74 medications in total were included 
in data collection (Figure 1, Supplemental Table 1).  
 
Data Analysis 
Descriptive statistics were used to assess demographics, clinical characteristics, 
CYP2C19 phenotype, and PGx actionable medication use in the full study population as well as 
the stratum that underwent CYP2C19 genetic testing. Data are reported as counts (%), mean ± 
standard deviation, or median [interquartile range] unless otherwise indicated. Analyses were 
performed using SAS-JMP Version 14.0 (Cary, NC). 
The primary endpoint was the observed number of potential PGx directed medication 
interventions that could have been made to optimize prescribing beyond antiplatelet therapy in 
the stratum of patients with CYP2C19 genotype results available (N=380). A potential 
intervention was defined as medication with a clinically actionable recommendation prescribed 
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to an individual that carried an at-risk CYP2C19 metabolizer phenotype (e.g., UM or PM). The 
total number of potential interventions, as well as the total number of unique patients with a 
potential intervention, were calculated to account for the possibility of multiple actionable 
CYP2C19-guided interventions within the same patient. The proportion of use by drug class and 
type of adverse outcome avoided (therapeutic failure or adverse event) were also calculated.  
A secondary simulation analysis was conducted to evaluate the projected impact of a 
multigene PGx testing strategy on medication prescribing in the overall PCI patient population 
(N=646). The simulation was designed to determine the number of PGx-guided interventions 
that could have been made based on genotype results in addition to CYP2C19. Actionable 
gene-drug pairs for which the drug was used in at least 2% of the study population were 
included. This resulted in inclusion of 6 genes in addition to CYP2C19 (CYP2C9, CYP2D6, 
G6PD, HLA-B, SLCO1B1 and VKORC1) and 19 medications in the analysis (Supplemental 
Table 2). At-risk genotype or phenotype frequencies, stratified by race, were abstracted from 
CPIC guideline supplements for CYP2C19 (UM, RM or PM), CYP2D6 (UM, IM or PM), 
SLCO1B1 (intermediate or low function), G6PD (deficient), and HLA-B (*58:01 carrier).[2,13,21–
25] For VKORC1/CYP2C9 (highly sensitive or sensitive warfarin responders), the ENGAGE AF-
TIMI 48 trial was used in addition to the warfarin CPIC guideline to estimate phenotype 
prevalence.[26,27] For genes without metabolizer phenotypes, in which only allele frequencies 
were available, the Hardy-Weinberg equation was used to estimate the frequencies of the 
actionable at-risk genotypes. Because panel-based genotype results were not available among 
the patients in this cohort, the simulation analysis projected the population genotype/phenotype 
frequency estimates for each gene onto the PCI study population, and assumed a population 
comprised of 80% Caucasian and 20% African-American patients. A potentially PGx actionable 
intervention was defined in the same manner as the primary outcome. The projected number of 
PGx-guided medication interventions that could have been made, if genotype results were 
available, was calculated by multiplying the observed frequency of medication use in the overall 
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study population by the estimated at-risk genotype/phenotype frequency for each medication. 
The sum of the total number of potential PGx directed interventions in the PCI study population 
(N=646), and the projected number of interventions per 100 PCI patients, were calculated for 




The mean age of the PCI population was 63±12 years, 70% were male, and 20% were 
African-American (Table 1). Approximately half of the patients had an acute coronary syndrome 
indication for their current PCI, while 53% had a previous revascularization procedure. Common 
comorbid conditions included hypertension (88%), obesity (46%), diabetes (40%) and 
psychiatric disorders (18%), while active cancer and end stage renal disease were prevalent in 
less than 5% of the cohort.  
 
Frequency of PGx actionable medication use in PCI patients  
Overall, clopidogrel was prescribed in 68% of the cohort, with an alternative P2Y12 
inhibitor (prasugrel or ticagrelor) prescribed in 32% of patients. The most commonly used PGx-
actionable medications in the study population beyond antiplatelet therapy were omeprazole, 
oxycodone, pantoprazole, tramadol, glipizide, hydrocodone, esomeprazole, warfarin, citalopram, 
simvastatin, ondansetron, allopurinol, sertraline, paroxetine, escitalopram, venlafaxine, 
amitriptyline, mirtazapine and glimepiride (Figure 2A, Supplemental Table 2). In addition, there 
were 18 PGx-actionable medications with observed use in less than 2% of the population that 
were collectively prescribed to 50 (7.7%) patients. When evaluated by therapeutic area (Figure 
2B), the proportion of PGx-actionable medications prescribed were most common for 
gastrointestinal indications (37%, proton pump inhibitors (PPI) and ondansetron), pain (26%, 
opioids), and mental health disorders (19%, selective serotonin reuptake inhibitors (SSRI) and 
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other antidepressants). Additional disease states with PGx-actionable medication use included 
CVD (9.4%, warfarin and simvastatin), diabetes (7.9%, sulfonylureas), and gout (3.6%, 
allopurinol). Of the CVD medications with FDA labeling information and CPIC Level C-D 
evidence, metoprolol (59%) and carvedilol (19%) were the most commonly used, followed by 
rosuvastatin (7.4%), hydralazine (3.7%) and propranolol (1.2%) (Supplemental Figure 1).   
 
Observed number of potential CYP2C19 genotype guided medication interventions 
CYP2C19 genotype was available in 380 (59%) patients following the index PCI 
procedure, with 92 (24%) patients having undergone genotype testing at a prior PCI procedure. 
Among the 288 patients genotyped at the time of the index PCI, the median [IQR] genotype 
turnaround time was 1 [0-2] day and results were available for 199 (69%) patients by the day 
after the test was ordered. Overall, the distribution of CYP2C19 phenotypes was 5% UM, 28% 
RM, 39% NM, 27% IM, and 2% PM (Figure 3A).  
Among the 380 PCI patients with a CYP2C19 genotype result, 194 (51%) were 
prescribed one or more of nine distinct PGx-actionable medications, beyond antiplatelet 
therapy, affected by CYP2C19 alleles (Figure 3B). As a result of 35 (9.2%) patients taking more 
than one PGx actionable medication, there were 229 total instances of a CYP2C19-affected 
medication being prescribed to a patient with a genotype result available in the EHR. As 
summarized in Table 2, we observed 30 instances in which a CYP2C19 UM, RM or PM was 
prescribed CYP2C19 metabolized medication (7.9 per 100 patients). As a result of 3 patients 
taking more than one medication, an actionable PGx intervention based on the genotype result 
could have been made in 27 (7.1%) of the 380 genotyped patients (13.9% of the 194 genotyped 
patients taking a medication affected by CYP2C19). The majority of the projected interventions 
would have served to avoid a potential therapeutic failure (87%) in a CYP2C19 UM or RM 




Projected number of potential PGx guided interventions following multigene testing 
 A simulation analysis estimating the potential impact of multigene testing for CYP2C19, 
CYP2D6, G6PD, VKORC1/CYP2C9, SLCO1B1, and HLA-B in the overall study population 
(N=646) projected that 113 total interventions (17.5 per 100 patients) beyond antiplatelet 
therapy could have been made based on actionable PGx results (Figure 4). A detailed 
summary, by gene and drug, is provided in Supplemental Tables 3-8.  
Among the 396 instances of CYP2C19 metabolized medication use, we estimated 55 
projected PGx interventions beyond antiplatelet therapy (8.5 per 100 patients; Supplemental 
Table 3). The most common projected interventions involved prevention of a potential SSRI (27 
interventions) and PPI (13 interventions) therapeutic failure in UMs or RMs, and avoidance of a 
potential PPI adverse effect in PMs (8 interventions). The number and distribution of projected 
interventions in the simulation analysis was consistent with our observed data in patients with 
available CYP2C19 genotype results.   
Among the 314 instances of CYP2D6 metabolized medication use, we estimated 29 
projected PGx interventions (4.5 per 100 patients; Supplemental Table 4). The projected 
interventions involved antidepressants (amitriptyline, paroxetine, venlafaxine) in CYP2D6 UMs, 
IMs and PMs (7 interventions), opioids (tramadol, oxycodone, hydrocodone) in CYP2D6 UMs 
and PMs (21 interventions), and ondansetron in CYP2D6 UMs (1 intervention). Among the 44 
and 41 patients taking warfarin and simvastatin, respectively, we projected 14 potential warfarin 
dose optimization interventions in VKORC1/CYP2C9 sensitive or highly sensitive responders 
(2.2 per 100 patients; Supplemental Table 5) and 10 potential interventions in patients with a 
SLC01B1 intermediate or low function phenotype that could be prescribed a lower dose or 
alternative statin (1.5 per 100 patients; Supplemental Table 6). We also projected 4 potential 
interventions in patients with G6PD deficiency taking glipizide or glimepiride (0.6 per 100 
patients; Supplemental Table 7), and 1 potential intervention for a patient taking allopurinol (0.2 
per 100 patients; Supplemental Table 8), which is contraindicated in HLA-B*58:01 allele 
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carriers.[28]   
 
Discussion  
The projected impact of CYP2C19 and multigene PGx testing on medications beyond 
clopidogrel was evaluated in a real-world cohort of patients that underwent PCI and CYP2C19 
testing. Our results demonstrate that medications with actionable PGx recommendations across 
multiple drug classes, most notably PPIs, antidepressants and opioids, are commonly 
prescribed in PCI patients. Among patients with an available CYP2C19 genotype result in the 
EHR, approximately 50% were prescribed a CYP2C19 metabolized medication beyond 
clopidogrel and 7% met criteria for a CYP2C19 genotype-guided medication intervention. 
Further, our simulation analysis projected that approximately 17.5 medication interventions per 
100 PCI patients could have been recommended if multigene PGx test results were available. 
Taken together, these results suggest that multigene PGx testing could be used to optimize 
prescribing for multiple medications beyond CYP2C19 genotype-guided antiplatelet therapy in 
PCI patients, and warrants further study.  
Due to the benefit of CYP2C19 genotype-guided antiplatelet therapy after PCI, use of 
CYP2C19 testing in clinical practice to optimize antiplatelet therapy after PCI has become 
increasingly common.[8,11,29] Our results demonstrate that an opportunity exists to optimize 
use of medications beyond clopidogrel based on the results of a CYP2C19 genotype test that 
has already been performed. Approximately 50% of PCI patients in our cohort were prescribed 
a CYP2C19 metabolized PPI or antidepressant at either discharge or an outpatient encounter 
within one-year, with approximately 7% of patients qualifying for an evidence-based CYP2C19 
genotype-guided medication intervention. In patients prescribed a PPI, interventions would 
include increasing the PPI dose in CYP2C19 UM patients to prevent therapeutic failure, and 
selecting an alternative PPI in CYP2C19 PM patients to avoid an adverse event.[30] In patients 
prescribed a SSRI, interventions would include selecting an alternative agent in CYP2C19 UM 
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or RM patients to avoid therapeutic failure, and either a dose reduction or alternative agent in 
CYP2C19 PM patients to avoid a potential adverse event.[22]  
Because it has been estimated that approximately 99% of the population carries at least 
one at-risk PGx genotype, identifying patient populations that are commonly prescribed PGx-
actionable medications is an important prerequisite for efficient implementation of multigene 
PGx testing.[6,7] In addition to PPIs and antidepressants, opioids for chronic pain, warfarin for 
thromboembolic disease, and simvastatin for hyperlipidemia also were commonly prescribed in 
PCI patients. Our simulation analysis projected that multigene testing in our study PCI 
population could have yielded 17.5 PGx-guided medication interventions per 100 patients, of 
which approximately half were derived from CYP2C19. The primary genes in addition to 
CYP2C19 yielding actionable results were CYP2D6 for antidepressants and opioids, 
VKORC1/CYP2C9 for warfarin, and SLCO1B1 for simvastatin. These observations are 
consistent with two recent analyses that demonstrated multigene testing with CYP2C19, 
SLCO1B1, VKORC1 and CYP2C9, and multigene testing with CYP2C19 and CYP2D6 was 
more cost effective than CYP2C19 testing alone in patients undergoing PCI.[31,32] Taken 
together, our results suggest the cardiac catheterization laboratory is a logical “foot in the door” 
setting for institutions to efficiently implement preemptive multigene PGx testing, and can be 
used to inform the design of prospective studies that evaluate the feasibility and impact of this 
precision medicine strategy in PCI patients. 
Results of our study demonstrating that approximately one of every six PCI patients met 
qualifications for a PGx-guided medication intervention beyond antiplatelet therapy may 
underestimate the value of preemptive genotyping since our analysis only considered 
prescribing during the 12 months after PCI. The number of interventions would be expected to 
increase over time as patients age and are prescribed additional medications. Furthermore, 
additional commonly prescribed medications with CPIC level C evidence, such as beta blockers, 
may be reclassified as clinically actionable as evidence supporting clinical use expands. 
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Considering additional medications with PGx actionable recommendations by the Dutch 
Pharmacogenetics Working Group (DPWG) would also likely increase the number of potential 
PGx-guided interventions in PCI patients. Our results also demonstrate that most PGx-guided 
interventions would serve to prevent a potential therapeutic failure. While the clinical impact of 
such medication optimization interventions might not be immediate, the longer-term effects 
could be significant to patients, providers and payers.  
Notably, SSRIs are the first line treatment for depression and anxiety, and treatment 
failures can lead to significant health consequences for patients and increased healthcare costs 
that are especially problematic in the elderly.[33] Moreover, suboptimal management of 
depression is associated with adverse cardiovascular outcomes.[34] Given that over a third of 
the U.S. population carries either a CYP2C19 or CYP2D6 UM or RM phenotype, PGx-guided 
strategies that enable more precise initial selection and dosing of antidepressants offer 
enormous potential to prevent or reduce the duration and impact of uncontrolled depressive 
symptoms.[22] Furthermore, CYP2D6 genotype-guided opioid prescribing has been shown to 
improve pain control, with emerging data also showing benefit in CYP2D6 IMs and PMs.[35] 
While the effect of CYP2C19 genotype on PPI pharmacokinetics has been well documented, 
the clinical significance on clinical outcomes remains less clear.[36] It has been suggested that 
genotype-guided PPI prescribing has clinical benefit in the treatment of gastroesophageal reflux 
disease (GERD) and H. pylori eradication, as well as the prevention of PPI-related adverse 
events such as infection and acute kidney injury.[30] Given the high prevalence of PPI use in 
PCI patients receiving antiplatelet therapy, studies evaluating the clinical effectiveness of 
CYP2C19 genotype-guided PPI prescribing are still needed. 
As multigene PGx testing becomes increasingly common in clinical practice, a more 
comprehensive assessment of multiple medications (rather than a single medication) will be 
necessary to effectively use each patient’s genetic test results to optimize prescribing decisions 
and minimize healthcare costs. Notably, our results showed that use of non-cardiac medications 
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in PCI patients is common. While this represents an opportunity for medication optimization to 
occur across a patient’s entire medication list, many PGx actionable medications are used to 
treat psychiatric and pain conditions that are not typically managed by a cardiologist. Clinical 
pharmacists, clinical decision support tools, and multi-disciplinary collaboration are instrumental 
to improve the adoption and appropriate use of PGx based medication optimization strategies, 
and facilitate transitions of care in patients with a multitude of comorbidities and 
medications.[37,38] Innovative precision medicine services, such as a precision medicine 
pharmacist in cardiology or multi-clinic settings, will become especially important as the 
frequency of PGx testing increases and new evidence linking genetic variation to suboptimal 
medication outcomes continues to emerge.   
There are several limitations to this study that should be acknowledged. The simulation 
analysis was limited by use of projected at-risk genotype frequencies and a probability-based 
estimation of potential PGx interventions in the overall population, rather than patient level data 
based on observed genotype results and medication use. However, the simulated CYP2C19 
analysis yielded very similar results to the observed analysis in patients with an available 
CYP2C19 genotype, which increases confidence in our results. Furthermore, clinical outcomes 
were not evaluated. The direct impact of PGx-guided prescribing on adverse medication 
outcomes will require prospective investigation in subsequent studies. Due to the retrospective 
design, the observed medication use frequency may not reflect more contemporary prescribing 
patterns. Although medication use was evaluated at multiple encounters over time, 
misclassification bias cannot be excluded. Further, medications used transiently, such as 
antibiotics, antifungals and anesthesiology drugs, were not included since our data abstraction 
strategy would likely underestimate their actual use. Notably, the antifungal voriconazole has 
actionable prescribing recommendations based on CYP2C19 genotype results.[39] Thus, 
exclusion of these medications from our analysis likely underestimated the projected impact of 
PGx testing in this population. Additionally, some patients likely receive some medications for 
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non-cardiac disease states at other centers that may not be documented in the EHR, further 
underestimating the number of actionable PGx recommendations. Lastly, although the study 
population was derived from an academic, tertiary referral center with a population that is 
approximately 20% African-American and representative of surrounding areas, medication use 
frequency at this single-center may not be generalizable to other PCI populations. Prospective 
studies in larger and more diverse multicenter populations, and over longer time-horizons after 
PCI, are warranted. In addition, future studies evaluating the projected impact of multigene PGx 
testing on medication optimization beyond PCI patients, and across multiple clinical settings, are 
needed. 
In summary, the current study demonstrated that medications across multiple drug 
classes with actionable PGx recommendations are commonly prescribed in PCI patients 
receiving antiplatelet therapy. The projected impact of PGx testing on optimal medication 
prescribing beyond clopidogrel in this real-world patient population suggests that multigene PGx 
testing could be beneficial among PCI patients who are already indicated for CYP2C19 
genotyping, and the cardiac catheterization laboratory could serve as a logical setting for 
institutions to efficiently implement multigene PGx testing into routine clinical practice. Future 
prospective studies evaluating the feasibility and effectiveness of multigene PGx testing in PCI 
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Figure Legends  
 
Figure 1. Overview of the number of PGx actionable medications included in data 
collection. The number of medications included in and excluded from data collection are 
described. The 74 medications included in data collection, and the associated gene and CPIC 
level of evidence, are listed in Supplemental Table 1. 
 
Figure 2. Frequency of PGx actionable medication use beyond antiplatelet therapy in PCI 
patients. (A) Use frequency of PGx actionable medications at discharge from the index PCI 
hospitalization (black) or initiation at an outpatient follow-up visit up to one-year post discharge 
(blue) in the overall study population (N=646). Medications used in ≥2% of patients, and the 
associated gene, are presented. *Other medications is a composite of 18 individual medications 
with <2% use frequency in the study population (listed in Supplemental Table 2). (B) The 
distribution of PGx actionable medication use by medication therapeutic area: gastrointestinal 
(GI), pain, mental health, cardiovascular (not including antiplatelet therapy and the CPIC Level 
C-D drugs described in Supplemental Figure 1), diabetes, gout, and other 
(immunosuppressants, antiviral, cancer, cystic fibrosis, and anticonvulsants). 
 
Figure 3. Observed frequency of CYP2C19 phenotypes and actionable medication use 
beyond antiplatelet therapy in genotyped PCI patients. (A) CYP2C19 phenotype distribution 
in 380 genotyped patients: ultrarapid (UM: n=17; 4%), rapid (RM: n=106; 28%), normal (NM: 
n=148; 39%), intermediate (IM: n=102; 27%); poor (PM: n=7; 2%) metabolizers. The IM 
[*1/*2=73 (72%), *1/*3=0 (0%), *2/*17=29 (28%), *3/*17=0 (0%)] and PM [*2/*2=7 (100%), 
*2/*3=0 (0%), *3/*3=0 (0%)] phenotypes included multiple genotypes. (B) Use frequency of PGx 
actionable medications affected by CYP2C19 metabolism beyond antiplatelet therapy in 
CYP2C19 genotyped patients, sorted by medication class. Rabeprazole and clomipramine use 
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was 0%, and thus not included in the graph. 
 
Figure 4. Projected number of actionable PGx interventions beyond antiplatelet therapy 
by gene in PCI patients. Based on a simulation analysis including the 19 most frequently 
prescribed medications and corresponding 7 genes with actionable PGx recommendations, the 
projected number of potential PGx interventions were calculated (as summarized in detail in 
Supplemental Tables 3-8). Data are presented, by gene, as the projected number of actionable 



































*Data presented as N (%) unless otherwise stated. 
† Genotype test performed at a prior PCI admission.  
^ Genotype test performed during the index PCI admission.   
 
  
Characteristic N (%)* 
N 646 
Age, years (mean ± SD) 63.3±11.9 
Male  453 (70.1%) 
Race/Ethnicity  
     Caucasian  461 (71.4%) 
     African American   128 (19.8%) 
     Asian  3 (0.5%) 
     Hispanic 22 (3.4%) 
     Native American  19 (2.9%) 
     Other/unknown 13 (2.0%) 
Obese (body mass index >30 kg/m2) 300 (46.4%) 
Current smoker 150 (23.2%) 
Hypertension  568 (87.9%) 
Diabetes 261 (40.4%) 
Depression or other psychiatric disorder 117 (18.1%) 
End stage renal disease 20 (3.1%) 
Active cancer 31 (4.8%) 
History of myocardial infarction 195 (30.2%) 
History of a prior revascularization procedure  345 (53.4%) 
Acute coronary syndrome indication for PCI 315 (48.8%) 
CYP2C19 genotype available 380 (58.8%) 
     Previously determined genotype† 92 (14.2%) 
     Genotype during current admission^ 288 (44.6%) 
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 Total 229   30  
 
PPI, proton pump inhibitor; PM, poor metabolizer, RM, rapid metabolizer; SSRI, selective 
serotonin reuptake inhibitor, TCA, tricyclic antidepressant; UM, ultrarapid metabolizer 
*The number of potential actionable PGx interventions count the number of observed instances 
where a CYP2C19 genotyped patient (n=380) was prescribed a CPIC Level A or B evidence 










(CPIC Level A or B evidence 
+ 6 CVD medications with 
PGx in the FDA label)




Exclude 7 medications 
(rare diseases or not 
used in the U.S.)
25 
 































































B PGx Actionable Medication Use by Therapeutic Area
26 
 
Figure 3: Observed frequency of CYP2C19 phenotypes and actionable medication use beyond 





































Figure 4: Projected number of actionable PGx interventions beyond antiplatelet therapy by 
















































ONLINE SUPPLEMENTAL MATERIAL 
 
 
Projected Impact of Pharmacogenomic Testing on Medications Beyond Antiplatelet 
Therapy in Percutaneous Coronary Intervention Patients 
 
  
Supplemental Figure 1. 
 
 
Supplemental Figure 1. Observed frequency of additional CVD medications with PGx 
information in the drug label. Use frequency of cardiovascular disease (CVD) medications 
with genetic information in the FDA label and CPIC Level C-D evidence at discharge from the 
index PCI hospitalization in the overall study population (N=646), sorted by medication class 
(beta-blockers: blue; statin: black; vasodilator: gray). Propafenone (anti-arrhythmic) use was 
0%, and thus not included in the graph. 
 
 



















Supplemental Table 1: List of 74 medications collected in the study population  
(sorted by CPIC level of evidence). 
 
Class Gene Medication 
CPIC Level 
of Evidence 
Anti-platelet CYP2C19 Clopidogrel A 
Cholesterol SLCO1B1 Simvastatin A 
Anticoagulant VKORC1 / CYP2C9 (CYP4F2) Warfarin A 
Antidepressant 
(TCA) 
CYP2D6 / CYP2C19 Amitriptyline A 














Anti-seizure HLA-B / HLA-A Carbamazepine A 
HLA-B / CYP2C9 Phenytoin A 
Immunosuppressive 










oxidase inhibitor) HLA-B Allopurinol A 
Gout (recombinant 
urate-oxidase) G6PD Rasburicase A 
Antiviral (HIV) 
HLA-B Abacavir A 
UGT1A1 Atazanavir A 








UGT1A1 Irinotecan A 
Anti-cancer  
(anti-estrogen) CYP2D6 Tamoxifen A 
Cystic Fibrosis CFTR Ivacaftor A 
  
Class Gene Medication 
CPIC Level 
of Evidence 
Anti-arrhythmic (Ia) CYP2D6 Quinidine B 
Antidepressant  
(TCA) 










CYP2C19 Sertraline B 
CYP2D6 Vortioxetine B 
Antidepressant (SNRI) CYP2D6 Venlafaxine B 
Antidepressant 
(multiple) CYP2D6 Mirtazapine B 
Antidepressant / 
antipsychotic CYP2D6 Aripiprazole B 
Antipsychotic CYP2D6 Brexpiprazole B 
Antipsychotic /  
Tourette syndrome CYP2D6 Pimozide B 
Antipsychotic CYP2D6 Risperidone B 
ADHD (SNRI) CYP2D6 Atomoxetine B 
Analgesic (NSAID) CYP2C9 Celecoxib B 
Analgesic (Opioid) CYP2B6 Methadone B 
Anti-seizure HLA-B Oxcarbazepine B 



















(HDAC inhibitor) UGT1A1 Belinostat B 
Anti-cancer G6PD Dabrafinib B 
  
Class Gene Medication CPIC Level 
of Evidence 





Cholesterol SLCO1B1 Rosuvastatin C 
Vasodilator NAT2 Hydralazine D 
 
* Although hydrocodone is metabolized by CYP2D6, and CPIC guidelines indicate it is not a good 
alternative to codeine in CYP2D6 ultrarapid or poor metabolizers (see Supplemental Table 4), 
hydrocodone does not have a CPIC Level of Evidence designation. 
The 36 medications with CPIC Level A of B evidence excluded from the analysis (due to transient use, 
treatment of a rare disease, or primary use outside of the United States) are listed here: acenocoumarol, 
chloramphenicol, chloroquine, ciprofloxacin, dapsone, desflurane, dextromethorphan/quinidine, 
dimercaprol, eliglustat, erythromycin, hydroxychloroquine, isoflurane, levofloxacin, lidocaine, mafenide, 
mefloquine, mesalazine, methylene blue, moxifloxacin, nalidixic acid, nitrofurantoin, norfloxacin, 
phenazopyridine, phenprocoumon, primaquine, quinine, sevoflurane, sodium nitrite, succinylcholine, 
sulfacetamide, sulfadiazine, sulfamethoxazole/trimethoprim, sulfasalazine, sulfisoxazole, and 
voriconazole. 
 
Supplemental Table 2: Summary of medication use for the PCI study population (N=646) 






Proton pump inhibitor omeprazole 163 25.2% B CYP2C19 
Analgesic (Opioid) oxycodone 113 17.5% A CYP2D6 
Proton pump inhibitor pantoprazole 76 11.8% B CYP2C19 
Analgesic (Opioid) tramadol 64 9.9% A CYP2D6 
Sulfonylurea glipizide 58 9.0% B G6PD 
Analgesic (Opioid) hydrocodone 50 7.7% - CYP2D6 
Proton pump inhibitor esomeprazole 46 7.1% B CYP2C19 
Anticoagulant warfarin 44 6.8% A VKORC1 / 
CYP2C9 
Antidepressant (SSRI) citalopram 43 6.7% A CYP2C19 
Statin simvastatin 41 6.3% A SLCO1B1 
Anti-emetic ondansetron          37 5.7% A CYP2D6 
Anti-gout (xanthane 
oxidase inhibitor) 
allopurinol 31 4.8% A HLA-B 
Antidepressant (SSRI) sertraline  30 4.6% B CYP2C19 
Antidepressant (SSRI) paroxetine 20 3.1% A CYP2D6 
Antidepressant (SSRI) escitalopram 16 2.5% A CYP2C19 
Antidepressant (SNRI) venlafaxine 16 2.5% B CYP2D6 




mirtazapine 13 2.0% B CYP2D6 
Sulfonylurea glimepiride 13 2.0% B G6PD 
Immunosuppressive 
(calcineurin inhibitor) 
tacrolimus 11 1.7% A CYP3A5 
Antidepressant (TCA) nortriptyline 7 1.1% A CYP2D6 
Antidepressant / 
antipsychotic 
aripiprazole 5 0.8% B CYP2D6 
Analgesic (Opioid) codeine  4 0.6% A CYP2D6 
Proton pump inhibitor dexlansoprazole 4 0.6% B CYP2C19 
Proton pump inhibitor lansoprazole 4 0.6% B CYP2C19 
Anti-cancer  
(anti-estrogen) 
tamoxifen 2 0.3% A CYP2D6 




azathioprine 2 0.3% A TPMT / 
NUDT15 
ADHD (SNRI) atomoxetine 1 0.2% B CYP2D6 
Antidepressant (SSRI) fluvoxamine 1 0.2% A CYP2D6 
Antipsychotic risperidone 1 0.2% B CYP2D6 
Analgesic (Opioid) methadone 1 0.2% B CYP2B6 
Analgesic (NSAID) celecoxcib  1 0.2% B CYP2C9 
Anti-gout pegloticase 1 0.2% B G6PD 
Antiviral (HIV) efavirenz 1 0.2% B CYP2B6 
Antiviral (HIV) abacavir 1 0.2% A HLA-B 
Cystic Fibrosis ivacaftor         1 0.2% A CFTR 
Medication use reflects use at discharge from the index PCI hospitalization or initiation during a 
follow-up visit within one year after the index PCI. 
The top 19 medications, with a use frequency of 2.0% or higher, were considered in the 
simulation analysis. 




































Avoid tertiary amine use. Consider alternative drug not 
metabolized by CYP2C19. If tertiary amine use 
warranted, use TDM to guide dose adjustments.
Optional Therapeutic failure
Poor metabolizer 2.5% 4.3% 0
Avoid tertiary amine use. Consider alternative drug not 
metabolized by CYP2C19. If tertiary amine use 
warranted, consider a 50% reduction in starting dose and 








396 55   Projected number of medication interventions (in the PCI study population, n=646)
8.5   Projected number of medication interventions (per 100 PCI patients)
CYP2C19 Phenotype Frequency source - PMID: 5974703 (SSRI CPIC guideline)
^ Calculation for each medication assumes that the study population is 80% Caucasion and 20% African-American






13 DPWG: consider dose increase by 50-100% No recommendation Therapeutic failure
8 FDA: use with caution; DPWG: No action required No recommendation
Dexlansoprazole
Therapeutic failure
Poor metabolizer 2.5% 4.3% 3
Consider 50% reduction of starting dose or consider 


























Poor metabolizer 2.5% 4.3%
A



































Avoid TCA use. Consider alternative drug not 
metabolized by CYP2D6. If a TCA is warranted, consider 





7.2% 13.2% 1 Consider a 25% reduction of recommended starting dose. Use TDM to guide dose adjustments. Moderate Adverse effects
Poor metabolizer 6.1% 3.0% 1
Avoid TCA use. Consider alternative drug not 
metabolized by CYP2D6. If a TCA is warranted, consider a 
50% reduction of recommended starting dose. Use TDM 




3.3% 3.4% 1 Select alternative drug not predominantlymetabolized by CYP2D6. Strong Therapeutic failure
Poor metabolizer 6.1% 3.0% 1
Select alternative drug not predominantly metabolized 
by CYP2D6. If paroxetine use warranted, consider a 50% 





3.3% 3.4% 1 DPWG: increase dose to 150% of the normal dose or select an alternative to venlafaxine No reccomendation Therapeutic failure
Intermediate/poor 
metabolizer




Use with caution. Tramadol is not a good alternative to 
codeine because its metabolism is affected by CYP2D6. 
DPWG: use an alternative to tramadol, or use 40% of the 
standard dose and monitor for side effects.
No reccomendation Adverse effects
Poor metabolizer 6.1% 3.0% 4
Use with caution. Tramadol is not a good alternative to 
codeine because its metabolism is affected by CYP2D6, 
and should be avoided
No reccomendation Therapeutic failure
Ultrarapid 
metabolizer
3.3% 3.4% 4 Use with caution. Oxycodone is not a good alternative to codeine because its metabolism is affected by CYP2D6. No reccomendation Adverse effects
Poor metabolizer 6.1% 3.0% 6
Use with caution. Oxycodone is not a good alternative to 
codeine because its metabolism is affected by CYP2D6, 
and should be avoided.




Use with caution. Hydrocodone is not a good alternative 
to codeine because its metabolism is affected by 
CYP2D6.
No reccomendation Adverse effects
Poor metabolizer 6.1% 3.0% 3
Use with caution. Hydrocodone is not a good alternative 
to codeine because its metabolism is affected by 
CYP2D6, and should be avoided.
No reccomendation Therapeutic failure
Anti-
emetic
Ondansetron         37 CYP2D6
Ultrarapid 
metabolizer
3.3% 3.4% 1 A PMID: 28002639
Select alternative drug not predominantly metabolized 
by CYP2D6.
Moderate Therapeutic failure 
314 29   Projected number of medication interventions (in the PCI study population, n=646)
4.5   Projected number of medication interventions (per 100 PCI patients)
CYP2D6 Phenotype Frequency source - PMID: 5974703 (SSRI CPIC guideline)
^ Calculation for each medication assumes that the study population is 80% Caucasion and 20% African-American
* In the absence of a specific recommendation by CPIC, the FDA and/or DPWG recommendation is provided






































































Sensitive responders 35.4% 8.9% 13 Lower dose requirement. Calculate dose based on PGx algorithms. Strong Adverse effects
Highly sensitive 
responders
2.9% 0.7% 1 Lower dose requirement. Calculate dose based on PGx algorithms. Strong Adverse effects
44 14   Projected number of medication interventions (in the PCI study population, n=646)
2.2   Projected number of medication interventions (per 100 PCI patients)
Warfarin Phenotype Frequency source - PMID: 28198005 (Wafarin CPIC guideline) and 25769357 (ENGAGE-TIMI 56 genetic substudy)
# Based on the VKORC1  and CYP2C9  minor allele frequencies, we assumed the warfarin sensitivity phenoytpes in African-Americans were one-fourth of the frequency in Caucasians












































26.8% 2.0% 9 Use lower dose or consider an alternative statin. Consider routine CK surveillance Strong Adverse effects 
Low function 2.5% 0.0% 1 Use lower dose or consider an alternative statin. Consider routine CK surveillance Strong Adverse effects 
41 10   Projected number of medication interventions (in the PCI study population, n=646)
1.5   Projected number of medication interventions (per 100 PCI patients)
SLCO1B1 Phenotype Frequency source - PMID: 22617227 (Simvastatin CPIC guideline)
^ Calculation for each medication assumes that the study population is 80% Caucasion and 20% African-American
PMID: 
22617227Statin Simvastatin 41 SLCO1B1 A

































Glipizide 58 G6PD deficient 3.9% 7.5% 3 B N/A
 FDA: Caution should be used in patients with G6PD 
deficiency and a non-sulfonylurea alternative should be 
considered.
No recommendation Adverse effect
Glimepiride 13 G6PD deficient 3.9% 7.5% 1 B N/A
FDA: Caution should be used in patients with G6PD 
deficiency and a non-sulfonylurea alternative should be 
considered.
No recommendation Adverse effect
71 4   Projected number of medication interventions (in the PCI study population, n=646)
0.6   Projected number of medication interventions (per 100 PCI patients)
G6PD Phenotype Frequency source - PMID: 4787449 (Rasburicase CPIC guideline)
^ Calculation for each medication assumes that the study population is 80% Caucasion and 20% African-American





































Anti-gout Allopurinol 31 HLA-B
HLA-B*58:01 allele 
carriers
1.6% 7.6% 1 A PMID: 23232549 Allopurinol use is contraindicated Strong 
Serious adverse 
event 
31 1   Projected number of medication interventions (in the PCI study population, n=646)
0.2   Projected number of medication interventions (per 100 PCI patients)
G6PD Phenotype Frequency source - PMID: 26094938 (Allopurinol CPIC guideline update)
^ Calculation for each medication assumes that the study population is 80% Caucasion and 20% African-American
